Optimizing Unrelated Donor Cord Blood Transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1 SUPPL., 2009, Pages 154-161

  Barker, Juliet N ^a   Rocha, Vanderson ^b   Scaradavou, Andromachi ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

Allogeneic transplantation; Alternative donors; Cord blood; Hematologic malignancy

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ARTICLE; CANCER REGISTRY; CD34 SELECTION; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; CRYOPRESERVATION; DISEASE FREE SURVIVAL; DONOR SELECTION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; MYELOABLATIVE CONDITIONING; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; RISK ASSESSMENT; WHOLE BODY RADIATION;

EID: 65249169255     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.10.020     Document Type: Article

References (25)

1. Kurtzberg J., Laughlin M., Graham M.L., et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335 (1996) 157-166
2. Gluckman E., Rocha V., Boyer-Chammard A., et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 337 (1997) 373-381
3. Rubinstein P., Carrier C., Scaradavou A., et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 339 (1998) 1565-1577
4. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100 (2002) 1611-1618
5. Arora M., Nagaraj S., Wagner J.E., et al. Chronic graft versus host disease following unrelated donor hematopoietic stem cell transplantation: higher response rate in recipients of unrelated donor umbilical cord blood. Biol Blood Marrow Transplant 13 (2007) 1145-1152
6. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of two partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
7. Brunstein C., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after non-myeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. Blood 110 (2007) 3064-3070
8. Brunstein C.G., Weisdorf D.J., Defor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of anti-thymocyte globulin to a non-myeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108 (2006) 2874-2880
9. Robin M., Marque-Juillet S., Scieux C., et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica 92 (2007) 1254-1257
10. Scaradavou A., Smith K., Hawke R., et al. CD34+ viability is a critical determinant of the engraftment potential of umbilical cord blood (UCB) in double unit transplantation. Blood 110 (2007) 600a
11. Barker J.N., Scaradavou A., Stevens C., and Rubinstein P. The dose-match interaction in umbilical cord blood (UCB) transplantation: an analysis of the impact of cell dose and hla-match on the disease-free survival (DFS) of 989 patients transplanted with single units for hematologic malignancy. Blood 110 (2007) 105a
12. Szabolcs P., and Niedzwiecki D. Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 9 (2007) 111-122
13. Parkman R., Cohen G., Carter S.L., et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 12 (2006) 919-927
14. Verneris M.R., Brunstein C., DeFor T.E., et al. Risk of relapse after umbilical cord blood transplantation (UCBT) in patients with acute leukemia: marker reduction in recipients of two units. Blood 106 (2005) 93a
15. Gluckman E., and Rocha V. Donor selection for unrelated cord blood transplants. Curr Opin Immunol 18 (2006) 565-570
16. Rocha V., Sanz G., and Gluckman E. Umbilical cord blood transplantation. Curr Opin Hematol 11 (2004) 375-385
17. Brunstein C.G., Setubal D.C., and Wagner J.E. Expanding the role of umbilical cord blood transplantation. Br J Haematol 137 (2007) 20-35
18. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 (2004) 2265-2275
19. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351 (2004) 2276-2285
20. Arcese W., Rocha V., Labopin M., et al. Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica 91 (2006) 223-230
21. Takahashi S., Iseki T., Ooi J., et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 104 (2004) 3813-3820
22. Dobrila L., Coelho P., Rubinstein P., et al. Transient warming events and cell viability of placental/umbilical cord blood (PCB) (2001), International Society for Hematotherapy and Graft Engineering, Quebec City, Canada
23. Dobrila L., Coelho P., Rubinstein P., et al. Cord blood viability: effects of volume reduction, cryopreservation and management (2004), 2nd Annual Meeting of AHA and Beijing International Symposium of Cord Blood Transplantation., Beijing, China
24. Migliaccio A.R., Adamson J.W., Stevens C.E., et al. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood 96 (2000) 2717-2722
25. Bone Marrow Donors Worldwide. Annual Report (2007)